Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepranolone in PMDD
NCT03697265Phase 2Completed
- Sponsor
- Asarina Pharma AB
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Allosteric Modulators
- Countries
- 4
01
Overview
A Phase 2 trial of sepranolone in Premenstrual Dysphoric Disorder (PMDD), sponsored by Asarina Pharma AB. Started Apr 2018; status: completed.
02
Drugs
sepranolone
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on NCT03697265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697265.